NCT06712173 is a Phase 1 clinical trial of linperlisib and SHR2554 in Peripheral T Cell Lymphoma, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT06712173?

NCT06712173 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT06712173?

Interventions in NCT06712173: linperlisib and SHR2554.

What condition does NCT06712173 study?

NCT06712173 studies Peripheral T Cell Lymphoma.

Is NCT06712173 still recruiting?

NCT06712173 is currently not yet recruiting. Last updated 2 December 2024.

Last reviewed 2024-12-02 · How we verify

NCT06712173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Not yet recruiting Phase 1 Last updated 2 December 2024

What this trial tests

Phase 1 trial testing linperlisib and SHR2554 in Peripheral T Cell Lymphoma in 33 participants. Not yet recruiting.

Timeline

1 December 2024

Primary endpoint
30 September 2025

31 March 2026

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 December 2024
Primary completion	30 September 2025
Estimated completion	31 March 2026

Drugs / interventions tested

linperlisib and SHR2554 — full drug profile →

Conditions studied

Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Peripheral T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the antitumor efficacy of the combination of the two drugs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Basis of Oncogenic PI3K Proteins.
Sheng Z, Beck P, Gabby M, Habte-Mariam S, et al · · 2024 · cited 1× · PMID 39796708 · DOI 10.3390/cancers17010077
Non-Histone Lysine Modifications in Tumor Microenvironment: Mechanisms and Therapeutic Opportunities.
Sun K, Xiao S, Huang Q, Zhang S, et al · · 2025 · PMID 41303712 · DOI 10.3390/ijms262211229

Verify or expand the search:

Other recruiting trials for Peripheral T Cell Lymphoma

Currently open trials in the same condition.

NCT07414758 — Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy · Phase 3 · recruiting
NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07389616 — A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell · Phase 2, PHASE3 · recruiting
NCT07353840 — T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR · recruiting
NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06712173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 2 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06712173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing